In 2023, the treatment success rate for HIV-positive tuberculosis in China was at 85%. Forecasted figures from 2024 to 2028 show a steady increase, reaching 89% by 2027 and stabilizing thereafter. Year-on-year growth highlights a 1% increment annually from 2024 to 2026, followed by a plateau in 2027 and 2028, indicating a sustained improvement in treatment outcomes. The compound annual growth rate (CAGR) over the next five years is approximately 0.9%.
Future trends to watch for include:
- Potential advancements in HIV and TB treatment methodologies.
- Policy changes affecting healthcare accessibility and treatment efficacy.
- Research developments in co-infection management strategies.
